Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.

  title={Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management.},
  author={Guillermo Garcia-Manero},
  journal={American journal of hematology},
  volume={89 1},
DISEASE OVERVIEW The myelodysplastic (MDS) are a very heterogeneous group of myeloid disorders characterized by peripheral blood cytopenias and increased risk of transformation to acute myelogenous leukemia (AML). MDS occurs more frequently in older male and in individuals with prior exposure to cytotoxic therapy. DIAGNOSIS Diagnosis of MDS is based on morphological evidence of dysplasia upon visual examination of a bone marrow aspirate and biopsy. Information obtained from additional studies… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 8 times over the past 90 days. VIEW TWEETS
41 Extracted Citations
82 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 41 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 82 references

Presence of TET2 mutation predicts a higher response rate to azacitidine in MDS and AML post MDS

  • R Itzykson, O Kosmider, T Cluzeau
  • Blood
  • 2010
Highly Influential
8 Excerpts

Current concepts in the pathophysiology and treatment of aplastic anemia. Blood 2006;108:2509–2519

  • NS Young, RT Calado, P. Scheinberg
  • PubMed PMID: 16778145
  • 2006
Highly Influential
4 Excerpts

Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplas ANNUAL CLINICAL UPDATES IN HEMATOLOGICAL MALIGNANCIES doi:10.1002/ajh.23642

  • H Kantarjian, Y Oki, G Garcia-Manero
  • American Journal of Hematology,
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…